Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Cell Infect Microbiol ; 11: 627917, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33968796

RESUMO

Candida albicans (C. albicans) is an opportunistic human fungal pathogen that can cause severe infection in clinic. Its incidence and mortality rate has been increasing rapidly. Amphotericin B (AMB), the clinical golden standard antifungal agent, has severe side effects that limit its clinical application. Thus, lowering the concentration and increasing the efficacy of AMB in a combinatorial antifungal therapy have been pursued by both industry and academia. Here we identify that fingolimod (FTY720), an immunomodulatory drug used for oral treatment of relapsing-remitting multiple sclerosis, can potentiate the efficacy of AMB against C. albicans growth synergistically. Furthermore, we observe an antifungal efficacy of FTY720 in combination with AMB against diverse fungal pathogens. Intriguingly, cells treated with both drugs are hypersensitive to endothelial endocytosis and macrophage killing. This is later found to be due to the hyperaccumulation of reactive oxygen species and the corresponding increase in activities of superoxide dismutase and catalase in the cells that received combinatorial treatment. Therefore, the combination of AMB and FTY720 provides a promising antifungal strategy.


Assuntos
Anfotericina B , Antifúngicos , Candida albicans , Cloridrato de Fingolimode , Humanos , Testes de Sensibilidade Microbiana
2.
Oncol Lett ; 21(6): 467, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33907577

RESUMO

The extent of lymph node (LN) dissection has been a topic of interest in gastric cancer (GC) surgery. D2 lymphadenectomy is considered the standard surgical procedure for most resectable advanced GC cases. The value and indications of more extended lymphadenectomy than D2 remain unclear. Currently, the controversial stations beyond the D2 range are mainly focused on no. 14v, no. 16a2/b1 and no. 13 LN stations. The metastatic rate of no. 14v LN is relatively high in advanced distal GC, particularly in patients with suspicious no. 6 LN metastasis. D2 plus no. 14v LN dissection may be attributed to improved survival outcomes for patients with obvious no. 6 LN metastasis. Although GC with para-aortic lymph node (PALN) metastases is considered an M1 disease beyond surgical cure, patients with limited PALN metastases may benefit from the treatment strategy of adjuvant chemotherapy followed by D2 plus no. 16a2-b1 LN dissection. In addition, D2 plus no. 13 LN dissection may be an option in a potentially curative gastrectomy for GC with duodenal invasion. The present review discusses the current status and future perspectives of D2 plus lymphadenectomy.

3.
Front Cell Dev Biol ; 9: 639233, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33693004

RESUMO

Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA in various areas of cancer management are attracting attention. In this review article, we discuss the potential relevance of using cfDNA analysis in clinical oncology, particularly in cancer screening, early diagnosis, therapeutic evaluation, monitoring disease progression; and determining disease prognosis.

4.
Nanotheranostics ; 5(1): 73-89, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33391976

RESUMO

Microfluidic chip is not a chip in the traditional sense. It is technologies that control fluids at the micro level. As a burgeoning biochip, microfluidic chips integrate multiple disciplines, including physiology, pathology, cell biology, biophysics, engineering mechanics, mechanical design, materials science, and so on. The application of microfluidic chip has shown tremendous promise in the field of cancer therapy in the past three decades. Various types of cell and tissue cultures, including 2D cell culture, 3D cell culture and tissue organoid culture could be performed on microfluidic chips. Patient-derived cancer cells and tissues can be cultured on microfluidic chips in a visible, controllable, and high-throughput manner, which greatly advances the process of personalized medicine. Moreover, the functionality of microfluidic chip is greatly expanding due to the customizable nature. In this review, we introduce its application in developing cancer preclinical models, detecting cancer biomarkers, screening anti-cancer drugs, exploring tumor heterogeneity and producing nano-drugs. We highlight the functions and recent development of microfluidic chip to provide references for advancing cancer diagnosis and treatment.


Assuntos
Técnicas Analíticas Microfluídicas/instrumentação , Neoplasias/diagnóstico , Antineoplásicos/uso terapêutico , Humanos , Neoplasias/tratamento farmacológico
5.
NPJ Precis Oncol ; 4(1): 33, 2020 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-33303906

RESUMO

The correlations between microbiota dysbiosis and cancer have gained extensive attention and been widely explored. As a leading cancer diagnosis worldwide, lung cancer poses a great threat to human health. The healthy human lungs are consistently exposed to external environment and harbor a specific pattern of microbiota, sharing many key pathological and physiological characteristics with the intestinal tract. Although previous findings uncovered the critical roles of microbiota in tumorigenesis and response to anticancer therapy, most of them were focused on the intestinal microbiota rather than lung microbiota. Notably, the considerable functions of microbiota in maintaining lung homeostasis should not be neglected as the microbiome dysbiosis may promote tumor development and progression through production of cytokines and toxins and multiple other pathways. Despite the fact that increasing studies have revealed the effect of microbiome on the induction of lung cancer and different disease status, the underlying mechanisms and potential therapeutic strategies remained unclear. Herein, we summarized the recent progresses about microbiome in lung cancer and further discussed the role of microbial communities in promoting lung cancer progression and the current status of therapeutic approaches targeting microbiome to alleviate and even cure lung cancer.

6.
Front Pharmacol ; 11: 579068, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33041823

RESUMO

Integrins are the adhesion molecules and receptors of extracellular matrix (ECM). They mediate the interactions between cells-cells and cells-ECM. The crosstalk between cancer cells and their microenvironment triggers a variety of critical signaling cues and promotes the malignant phenotype of cancer. As a type of transmembrane protein, integrin-mediated cell adhesion is essential in regulating various biological functions of cancer cells. Recent evidence has shown that integrins present on tumor cells or tumor-associated stromal cells are involved in ECM remodeling, and as mechanotransducers sensing changes in the biophysical properties of the ECM, which contribute to cancer metastasis, stemness and drug resistance. In this review, we outline the mechanism of integrin-mediated effects on biological changes of cancers and highlight the current status of clinical treatments by targeting integrins.

7.
Pathol Res Pract ; 215(10): 152567, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31383535

RESUMO

OBJECTIVE: This paper aims to provide some experimental basis for unveiling the role of PDRG1 (P53 And DNA Damage-Regulated Gene 1) gene silencing in the growth and development of gastric cancer. METHODS: PDRG1 levels in gastric cancer tissues and cell lines were measured by Western blotting. Then, gastric cancer BGC-823 cells, divided into Control, PDRG1 siRNA, NC siRNA and PDRG1 siRNA + KU55933 (ATM inhibitor) groups, were used to conduct a series of in vitro experiments including MTT, Flow cytometry, Wound-healing and Transwell assays. Expression of PDRG1 and ATM/p53 pathway-related proteins were determined by Western blot. Eventually, experiment in vivo was carried out to verify the control of PDRG1 on gastric cancer cells after establishing the tumor xenograft model in nude mice. RESULTS: PDRG1 was significantly elevated in gastric cancer tissues and was associated with lower cell differentiation degree, more severe lymph node metastasis and higher tumor stage of gastric cancer patients. The growth of BGC-823 cells were significantly retarded and the cell apoptosis was increased in the PDRG1 siRNA group; besides, cell cycle was arrested in G2/M phase, and the expressions of p-ATM, p53, p21, p-cdc2 and cleaved caspase-3 were up-regulated with the reduced PDRG1. However, KU55933 could reverse the anti-tumor effect of PDRG1 siRNA on BGC-823 cells. The in-vivo experiment confirmed PDRG1 siRNA can inhibit tumor xenograft growth in nude mice. CONCLUSION: Specific PDRG1 gene silencing may inhibit the growth and metastasis of gastric cancer cells through the activation of ATM/p53 pathway.


Assuntos
Apoptose/genética , Proteínas de Ligação a DNA/genética , Inativação Gênica , Neoplasias Gástricas/genética , Estômago/patologia , Adulto , Animais , Pontos de Checagem do Ciclo Celular/genética , Linhagem Celular Tumoral , Proliferação de Células/genética , Feminino , Humanos , Metástase Linfática/genética , Metástase Linfática/patologia , Masculino , Camundongos , Camundongos Nus , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Transdução de Sinais/genética , Neoplasias Gástricas/patologia
8.
J Nanosci Nanotechnol ; 18(7): 4720-4727, 2018 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-29442650

RESUMO

A LiFePO4/C composite fiber membrane was fabricated by the electrospinning method and subsequent thermal treatment. The thermal decomposition process was analyzed by TG/DSC, the morphology, microstructure and composition were studied using SEM, TEM, XRD, Raman, respectively. The results indicated that the prepared LiFePO4/C composite fibers were composed of nanosized LiFePO4 crystals and amorphous carbon coatings, which formed a three dimensional (3D) long-range networks, greatly enhanced the electronic conductivity of LiFePO4 electrode up to 3.59× 10-2 S · cm-2. The 3D LiFePO4/C fiber membrane could be directly used as a binder-free, self-standing cathode for lithium-ion battery, and exhibited an improved capacity and rate performance. The LiFePO4/C composite electrode delivered a discharge capacity of 116 mAh·g-1, 109 mAh·g-1, 103 mAh·g-1, 91 mAh·g-1, 80 mAh·g-1 at 0.1 C, 0.5 C, 1 C, 3 C, 5 C, respectively. And a stable cycling performance was also achieved that the specific capacity could retain 75 mA·g-1 after 500 cycles at 5 C. Therefore, this LiFePO4/C composite fiber membrane was promising to be used as a cathode for power lithium ion battery.

9.
R Soc Open Sci ; 4(7): 170323, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28791160

RESUMO

Improving the specific capacity and electronic conductivity of TiO2 can boost its practical application as a promising anode material for lithium ion batteries. In this work, a three-dimensional networking oxygen-deficient nano TiO2-x/carbon fibre membrane was achieved by combining the electrospinning process with a hot-press sintering method and directly used as a self-standing anode. With the synergistic effects of three-dimensional conductive networks, surface oxygen deficiency, high specific surface area and high porosity, binder-free and self-standing structure, etc., the nano TiO2-x/carbon fibre membrane electrode displays a high electrochemical reaction kinetics and a high specific capacity. The reversible capacity could be jointly generated from porous carbon, full-lithiation of TiO2 and interfacial lithium storage. At a current density of 100 mA g-1, the reversible discharge capacity can reach 464 mA h g-1. Even at 500 mA g-1, the discharge capacity still remains at 312 mA h g-1. Compared with pure carbon fibre and TiO2 powder, the TiO2-x/C fibre membrane electrode also exhibits an excellent cycle performance with a discharge capacity of 209 mA h g-1 after 700 cycles at the current density of 300 mA g-1, and the coulombic efficiency always remains at approximately 100%.

10.
Acta Pharmacol Sin ; 37(11): 1509-1515, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27569392

RESUMO

AIM: To examine the biological consequences and demographic factors that might affect the pharmacokinetics of vitamin D3 after a single high dose intervention in a young Chinese population with vitamin D insufficiency status. METHODS: A total of 28 young subjects (25 to 35 years old) with vitamin D insufficiency status [serum 25(OH)D <30 ng/mL] was recruited in Shanghai, China. The subjects were orally administered a single high dose of vitamin D3 (300 000 IU). Baseline characteristics and blood samples were collected at d 0, 1, 2, 3, 7, 28, 56, 84 and 112 after the intervention. The blood biomarker levels were determined with standardized methods. RESULTS: The intervention markedly increased the blood 25(OH)D3 levels within the first five days (mean Tmax=5.1±2.1 d) and sustained an optimal circulating level of 25(OH)D3 (≥30 ng/mL) for 56 d. After the intervention, body weight and baseline 25(OH)D3 levels were significantly correlated with circulating 25(OH)D3 levels. No adverse events and no consistently significant changes in serum calcium, creatinine, glucose, parathyroid hormone, vitamin D binding protein, or the urinary calcium/reatinine ratio were observed. However, there was a significant increase in phosphorus after the vitamin D3 intervention. Total cholesterol and triglyceride levels were decreased at the end of the trial. CONCLUSION: The pharmacokinetics of vitamin D after intervention were influenced by baseline 25(OH)D3 levels and the body weight of the subjects. The results suggest that a single high oral vitamin D3 intervention is safe and efficient for improving the vitamin D status of young Chinese people with vitamin D insufficiency.


Assuntos
Calcifediol/sangue , Colecalciferol/farmacocinética , Vitaminas/farmacocinética , Administração Oral , Adulto , Fatores Etários , Colecalciferol/administração & dosagem , Feminino , Humanos , Masculino , Fatores Sexuais , Fatores de Tempo , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/tratamento farmacológico , Vitaminas/administração & dosagem
11.
Anticancer Drugs ; 27(1): 60-5, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26375684

RESUMO

The aim of this research was to study the pharmacokinetic characteristics of a slow-release 5-fluorouracil implant as well as to evaluate the clinical drug activity of this preparation in pancreatic cancer patients. Pharmacokinetic characteristics of the slow-release 5-fluorouracil implant were evaluated by examining the half-life time (T1/2) and apparent volume of distribution (Vd) in pancreatic cancer patients; the slow-release 5-fluorouracil implant was administered through interstitial chemotherapy (tumor interstitium implantation). In the drug activity study, 36 locally advanced unresectable pancreatic cancer patients were divided randomly into an experimental treatment group (n=18) and a standard treatment group (n=18). The experimental treatment group was treated with interstitial chemotherapy of a slow-release 5-fluorouracil implant combined with systemic chemotherapy of gemcitabine; the standard treatment group was treated with systemic chemotherapy of gemcitabine. An internal drainage procedure was used when biliary and/or gastrointestinal tract obstruction occurred in the two groups. Clinical benefit response, including pain (visual analogue scale), analgesic drug use, general conditions (Karnofsky performance score), weight changes, and survival status, was observed. T1/2 of the slow-release 5-fluorouracil implant was 5475.8±136.4 min, whereas Vd was 45275.0±1028.6 l. Clinical benefit response in the experimental treatment group was better than that in the standard treatment group. The experimental treatment group had longer median survival time compared with the standard treatment group. The slow-release 5-fluorouracil implant could deliver drugs mainly in the regional area of the tumor and prolong the drug action time; interstitial chemotherapy of a 5-fluorouracil implant combined with systemic chemotherapy of gemcitabine could improve the quality of life and survival status of pancreatic cancer patients. The method was promising and worthy of in-depth investigations.


Assuntos
Antineoplásicos/farmacocinética , Fluoruracila/farmacocinética , Neoplasias Pancreáticas/tratamento farmacológico , Antineoplásicos/administração & dosagem , Implantes de Medicamento , Feminino , Fluoruracila/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Análise de Sobrevida
12.
Biomaterials ; 35(19): 5226-39, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24695093

RESUMO

Combinations of drugs promoting anti-angiogenesis and apoptosis effects are meaningful for cancer therapy. In the present study, dual peptides-modified liposomes were designed by attaching two receptor-specific peptides, specifically low-density lipoprotein receptor-related protein receptor (Angiopep-2) and neuropilin-1 receptor (tLyP-1) for brain tumor targeting and tumor penetration. Vascular endothelial growth factor (VEGF) siRNA and chemotherapeutic docetaxel (DTX) were chosen as the two payloads because VEGF is closely associated with angiogenesis, and DTX can kill tumor cells efficiently. Binding to glioma cells, co-delivery of siRNA and DTX in human glioblastoma cells (U87 MG) and murine brain microvascular endothelial cells (BMVEC), VEGF gene silencing, antiproliferation and anti-tumor effects of the dual peptides-modified liposomes were evaluated in vitro and in vivo. The dual peptides-modified liposomes persisted the binding ability to glioma cells, enhanced the internalization via specific receptor mediated endocytosis and tissue penetration, thus the dual peptides-modified liposomes loading VEGF siRNA and DTX possessed stimulative gene silencing and antiproliferation activity compared with non-modified and single peptide-modified liposomes. The co-delivery research revealed different intracellular behavior of hydrophilic large molecular and lipophilic small molecule, the former involves endocytosis and subsequent escape of endosome/lysosomes, while the latter experiences passive diffusion of lipophilic small drugs after its release. Furthermore, the dual peptides-modified liposomes showed superiority in anti-tumor efficacy, combination of anti-angiogenesis by VEGF siRNA and apoptosis effects by DTX, after both intratumor and system application against mice with U87 MG tumors, and the treatment did not activate system-associated toxicity or the innate immune response. Combination with the dual peptides-guided tumor homing and penetration, the dual peptides-modified liposomes provide a strategy for effective targeting delivery of siRNA and DTX into the glioma cell and inhibition of tumor growth in a synergistic manner.


Assuntos
Glioma/tratamento farmacológico , Lipossomos/química , Peptídeos/química , RNA Interferente Pequeno/administração & dosagem , Taxoides/administração & dosagem , Taxoides/uso terapêutico , Animais , Linhagem Celular Tumoral , Docetaxel , Humanos , Masculino , Camundongos , Camundongos Nus
13.
Acta Pharmacol Sin ; 34(9): 1237-42, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23770984

RESUMO

AIM: Ginger rhizome is used worldwide as a spicy flavor agent. This study was designed to explore the potential effects of pungent ginger components, 6-, 8-, and 10-gingerol, on human cytochrome P450 (CYP450) enzymes that are responsible for the metabolism of many prescription drugs. METHODS: The activities of human CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were analyzed using Vivid P450 assay kits. The mRNA expression of CYP3A4 in human hepatocellular carcinoma cell line HepG2 was measured using quantitative real-time PCR assay. RESULTS: All three gingerols potently inhibited CYP2C9 activity, exerted moderate inhibition on CYP2C19 and CYP3A4, and weak inhibion on CYP2D6. 8-Gingerol was the most potent in inhibition of P450 enzymes with IC50 values of 6.8, 12.5, 8.7, and 42.7 µmol/L for CYP2C9, CYP2C19, CYP3A4, and CYP2D6, respectively. By comparing the effects of gingerols on CYP3A4 with three different fluorescent substrate probes, it was demonstrated that the inhibition of gingerols on CYP3A4 had no substrate-dependence. In HepG2 cells, 8-gingerol and 10-gingerol inhibited, but 6-gingerol induced mRNA expression of CYP3A4. CONCLUSION: 6-, 8-, and 10-gingerol suppress human cytochrome P450 activity, while 8- and 10-gingerol inhibit CYP3A4 expression. The results may have an implication for the use of ginger or ginger products when combined with therapeutic drugs that are metabolized by cytochrome P450 enzymes.


Assuntos
Catecóis/farmacologia , Inibidores das Enzimas do Citocromo P-450 , Sistema Enzimático do Citocromo P-450/fisiologia , Álcoois Graxos/farmacologia , Gengibre , Relação Dose-Resposta a Droga , Células Hep G2 , Humanos
14.
Acta Pharmacol Sin ; 34(8): 1101-7, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23708556

RESUMO

AIM: To investigate the embryotoxicity of dihydroartemisinin (DHA), the main active metabolite of artemisinin, in zebrafish, and explore the corresponding mechanisms. METHODS: The embryos of wild type and TG (flk1:GFP) transgenic zebrafish were exposed to DHA. Developmental phenotypes of the embryos were observed. Development of blood vessels was directly observed in living embryos of TG (flk1:GFP) transgenic zebrafish under fluorescence microscope. The expression of angiogenesis marker genes vegfa, flk1, and flt1 in the embryos was detected using real-time PCR and RNA in situ hybridization assays. RESULTS: Exposure to DHA (1-10 mg/L) dose-dependently caused abnormal zebrafish embryonic phenotypes in the early developmental stage. Furthermore, exposure to DHA (10 mg/L) resulted in more pronounced embryonic angiogenesis in TG (flk1:GFP) zebrafish line. Exposure to DHA (10 mg/L) significantly increased the mRNA expression of vegfa, flk1, and flt1 in the embryos. Knockdown of the flk1 protein partially blocked the effects of DHA on embryogenesis. CONCLUSION: DHA causes abnormal embryonic phenotypes and promotes angiogenesis in zebrafish early embryonic development, demonstrating the potential embryotoxicity of DHA.


Assuntos
Artemisia/toxicidade , Artemisininas/toxicidade , Embrião não Mamífero/efeitos dos fármacos , Embrião não Mamífero/embriologia , Neovascularização Patológica/induzido quimicamente , Peixe-Zebra/embriologia , Animais , Animais Geneticamente Modificados , Embrião não Mamífero/patologia , Desenvolvimento Embrionário/efeitos dos fármacos , Desenvolvimento Embrionário/fisiologia , Neovascularização Patológica/patologia , Peixe-Zebra/genética
15.
Biomaterials ; 34(20): 4849-59, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23541420

RESUMO

A nanocarrier delivery system that can simultaneously deliver a chemotherapeutic drug and siRNA to the tumor is emerging as a promising treatment strategy for cancer treatment. In this study, a multifunctional PHD/PPF/siRNA complexes was developed by one-step assembly of prefunctionalized polymers: PEI-HZ-DOX (PHD) and PEI-PEG-Folate (PPF) with siRNA. The PHD, a conjugate of PEI (polyethylenimine) with doxorubicin (DOX) via a pH-responsive hydrazone linkage, enables pH-controlled drug release. The PPF, a tumor-targeting folate ligand conjugated to PEI using polyethyleneglycol (PEG) as a linker, enables immune evasion and cell-specific targeting. The prefunctionalized PHD and PPF as well as the self-assembly complexes reveals advantage on safety in further application for siRNA delivery. By exploiting distinct triple ratios of PHD, PPF and siRNA during nanocomplexes formulation, the folate surface density, DOX loading amount and siRNA complexation can be precisely and reproducibly changed. The studies showed that the complexes was capable of delivering siRNA and DOX to cancerous cells and release synchronously in cell by acid-triggered manner, i.e. hydrazone bond cleavage and endosome/lysosome escape using flow cytometry and confocal laser scanning microscopy analysis. The results highlight the potential for therapeutic gene silencing in vitro and in vivo using RT-PCR and non-invasive in vivo imaging systems. The PHD/PPF/siRNA complexes can increase DOX and siRNA accumulation in cancerous cells and decrease the nonspecific distribution in normal tissues by the combination of EPR effect of nanocarriers, pH-triggered drug release, folate-mediated targeted delivery, and synergistic action of DOX and siRNA.


Assuntos
Doxorrubicina/uso terapêutico , Sistemas de Liberação de Medicamentos , Ácido Fólico/análogos & derivados , Técnicas de Transferência de Genes , Neoplasias/tratamento farmacológico , Polietilenoglicóis/química , Polietilenoimina/química , RNA Interferente Pequeno/administração & dosagem , Animais , Doxorrubicina/farmacologia , Endossomos/efeitos dos fármacos , Endossomos/metabolismo , Feminino , Ácido Fólico/síntese química , Ácido Fólico/química , Inativação Gênica/efeitos dos fármacos , Células HeLa , Humanos , Hidrazonas/química , Concentração de Íons de Hidrogênio/efeitos dos fármacos , Espaço Intracelular/efeitos dos fármacos , Espaço Intracelular/metabolismo , Ligantes , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Neoplasias/metabolismo , Neoplasias/patologia , Polietilenoglicóis/síntese química , Polietilenoimina/síntese química , RNA Interferente Pequeno/metabolismo , Distribuição Tecidual/efeitos dos fármacos
16.
Chin Med J (Engl) ; 125(11): 1899-902, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22884050

RESUMO

BACKGROUND: Roux-en-Y gastric bypass (GBP) is the main surgical procedure used in type 2 diabetes. The objective of this study was to evaluate the different types of GBP in treatment of type 2 diabetes. METHODS: Patients with type 2 diabetes were randomly divided into two groups: those who underwent gastrojejunal loop anastomosis bypass and those who underwent gastrojejunal Roux-en-Y bypass. Blood glucose alterations, operation time, and operation complications were observed. RESULTS: Gastrojejunal loop anastomosis bypass and gastrojejunal Roux-en-Y bypass were both effective in the treatment of selected patients with type 2 diabetes. Compared with gastrojejunal Roux-en-Y bypass, gastrojejunal loop anastomosis bypass had the advantages of easier implementation, shorter operation time, and fewer operation complications. CONCLUSIONS: Gastrojejunal loop anastomosis is effective in treatment of type 2 diabetes. It is safe, easy to implement, and worthy of clinical popularization.


Assuntos
Diabetes Mellitus Tipo 2/cirurgia , Derivação Gástrica/métodos , Adulto , Anastomose em-Y de Roux , Glicemia/metabolismo , Diabetes Mellitus Tipo 2/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
17.
Anticancer Drugs ; 21(6): 600-8, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20527722

RESUMO

The aim was to develop a slow-release poly-lactic-coglycolic acid (PLGA)-oxaliplatin microsphere and to assess the therapeutic effectiveness and safety of this preparation on colorectal tumor in vivo. The PLGA-oxaliplatin microsphere was prepared based on a spray-drying method, and the drug loading and in-vitro oxaliplatin release profile were carried out using high performance liquid chromatography. The inhibiting effect on tumor growth was examined using in-vivo subcutaneously inoculated colorectal tumor models of nude mice. The size of the microsphere was less than 100 microm, drug loading was 18-22% and drug release time lasted as long as 30 days. PLGA-oxaliplatin microspheres significantly restrained tumor growth and this effect correlated with decreased expression of proliferating cell nuclear antigen and increased expression of terminal deoxynucleotidyltransferase dUTP nick end labeling in tumor cells. Bodyweight measurement and blood analysis did not suggest significant adverse effects on the mice during the study. The PLGA-oxaliplatin microsphere developed here was suitable for regional use; it appears safe and effective in controlling the tumor growth. This preparation shows promise in reducing local recurrence of colorectal cancer after resection, but needs further investigation.


Assuntos
Antineoplásicos/administração & dosagem , Neoplasias Colorretais/tratamento farmacológico , Ácido Láctico/química , Compostos Organoplatínicos/administração & dosagem , Ácido Poliglicólico/química , Animais , Antineoplásicos/uso terapêutico , Linhagem Celular Tumoral , Preparações de Ação Retardada , Feminino , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Microesferas , Compostos Organoplatínicos/uso terapêutico , Oxaliplatina , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Resultado do Tratamento
18.
Zhonghua Wei Chang Wai Ke Za Zhi ; 13(1): 57-9, 2010 Jan.
Artigo em Chinês | MEDLINE | ID: mdl-20099164

RESUMO

OBJECTIVE: To study the antitumor effect of peri-tumor implantation of delayed-release 5-fluorouracil implants on xenograft colorectal tumor in mice. METHODS: Fifty tumor-bearing nude mice were randomly divided into 5 groups. Group A and B were treated with peri-tumor implantation of 5-fluorouracil implants and the dose of 5-fluorouracil was 200 and 100 mg/kg, respectively. Group C and D were treated with peri-tumor injection of 5-fluorouracil solution and the dose of 5-fluorouracil was 200 and 100 mg/kg, respectively. Group E did not receive any treatment. A growth curve was plotted for changes in tumor volume, the weight of the tumor was measured and tumor inhibition rate was calculated. RESULTS: The growth curve was mild in group A and B and steep in group C, D and E. There were statistical differences in tumor volume between groups A and B and other groups and there were no statistical differences in tumor volume among group C, D and E. After 12 days, tumor inhibition rate was 72% in group A, 51% in group B, 8% in group C, and 5% in group C. There were statistical differences in inhibition rate between group A, B and C, D (P<0.05). The weight changes before and after the treatment among the 5 groups were not statistically different. During the study, 1 mouse in group A died, 4 in group C and 1 in group D. CONCLUSION: Delayed-release 5-fluorouracil implants can effectively inhibit tumor growth.


Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Neoplasias Colorretais/tratamento farmacológico , Fluoruracila/administração & dosagem , Animais , Preparações de Ação Retardada , Feminino , Masculino , Camundongos , Camundongos Nus , Ensaios Antitumorais Modelo de Xenoenxerto
19.
Zhonghua Yi Xue Za Zhi ; 87(36): 2531-3, 2007 Sep 25.
Artigo em Chinês | MEDLINE | ID: mdl-18067824

RESUMO

OBJECTIVE: To report the experience in the diagnosis and treatment of focal nodular hyperplasia (FNH) of liver. METHODS: The clinical data of 23 patients with FND in liver, 15 males and 8 females, aged 38 (22 - 53), were analyzed retrospectively. RESULTS: Thirteen of the 23 patients had been diagnosed as with FNH of liver before operation. The diagnosis of 12 cases was confirmed by CT or MRI. One case underwent ultrasonography guided biopsy. The diameters of tumor ranged 0.8 - 8 cm. All the 23 patients underwent resection of tumor with an uneventful recovery and without recurrence during the follow-up period. Altogether 27 tumor nodes had been resected. The diagnosis was confirmed by histological examination in all of the patients. CONCLUSION: CT and MRI are valuable for the diagnosis of FH of liver. Biopsy guided by ultrasonography leads to histological diagnosis. However, definite preoperative diagnosis remains difficult to make. Surgical resection is necessary when the patient becomes symptomatic or when malignancy cannot be excluded.


Assuntos
Hiperplasia Nodular Focal do Fígado/diagnóstico , Hiperplasia Nodular Focal do Fígado/cirurgia , Adulto , Feminino , Humanos , Fígado/diagnóstico por imagem , Fígado/patologia , Fígado/cirurgia , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tomografia Computadorizada por Raios X
20.
Zhonghua Wei Chang Wai Ke Za Zhi ; 9(3): 210-3, 2006 May.
Artigo em Chinês | MEDLINE | ID: mdl-16721679

RESUMO

OBJECTIVE: To investigate the risk factors for local recurrence and distant metastasis after radical anterior resection for rectal cancer. METHODS: Clinicopathological data of 957 patients who underwent radical anterior resection for rectal cancer from 1983 to 2000 were reviewed retrospectively. The risk factors for local recurrence and distant metastasis were analyzed. RESULTS: There were 150 recurrent or metastatic cases (15.7%) after radical resection during a median follow- up of 71 months. Recurrence and metastasis sites included pelvics(6.0%, n=57), liver (4.9%, n=47), lung (4.2%, n=40) and other sites (0.6%, n=6). The median recurrent interval was 18 months (2-85 months),with a median survival of 8 months (1-62 months) after recurrence. Re-resection of the tumors was performed in 23 patients(15.3% ), and the median survival of such patients was 30 months with a 5- year survival rate of 13.0%. There were significant differences in recurrence and metastasis considering age,family history of tumor,CEA level,T staging,lymph node metastasis,venous cancerous emboli and signet cell carcinoma or mucinous adenocarcinoma. Logistic regression analysis revealed that family history (P=0.001), high CEA level (P=0.033), T3- 4 (P=0.000), lymph node metastasis (P=0.000),venous cancerous emboli (P=0.001),and signet cell carcinoma or mucinous adenocarcinoma (P=0.012) were risk factors for recurrence and metastasis. CONCLUSIONS: There are several risk factors for recurrence after radical anterior resection for rectal cancer. The main recurrent or metastatic sites are pelvis,liver and lung. Resection of recurrent tumor can prolong the survival.


Assuntos
Recidiva Local de Neoplasia/etiologia , Neoplasias Retais/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Neoplasias Retais/diagnóstico , Neoplasias Retais/cirurgia , Estudos Retrospectivos , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...